Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
- Status
- RECRUITING
- Phase
- NA
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Status
- RECRUITING
- Phase
- PHASE2
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Status
- RECRUITING
- Phase
- PHASE3
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- Status
- RECRUITING
- Phase
- PHASE2
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE3
Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia
- Status
- WITHDRAWN
- Phase
- PHASE4
Alvocade® (Bortezomib) Safety and Effectiveness Study
- Status
- COMPLETED
- Phase
- N/A
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
- Status
- RECRUITING
- Phase
- PHASE2
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
- Status
- RECRUITING
- Phase
- NA
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Status
- RECRUITING
- Phase
- PHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Status
- RECRUITING
- Phase
- PHASE2